Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CARTER T DAVIS

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1407146418
CMS profile
3120894
Location
NEW ORLEANS, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$19,703.80

54 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $15,701.00 11
Food and Beverage $2,433.08 37
Travel and Lodging $1,569.72 6

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 2; records 51–54 of 54 matching records. This page contains 4 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CARTER T DAVIS

NPI 1407146418 · CMS profile ID 3120894

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

NEW ORLEANS, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–54 of 54 matching records. This page contains 4 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1407146418?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CARTER T DAVIS, NPI 1407146418, CMS profile ID 3120894. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–54 of 54 matching records. This page contains 4 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1407146418?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). CARTER T DAVIS, NPI 1407146418, CMS profile ID 3120894. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–54 of 54 matching records. This page contains 4 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1407146418?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
CARTER T DAVIS, NPI 1407146418, CMS profile ID 3120894, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–54 of 54 matching records. This page contains 4 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1407146418?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

54 matching records · $19,703.80 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 54 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–54 of 54.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
E.R. Squibb & Sons, L.L.C. $247.0002/15/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101207064 CMS
ABBVIE INC. $100.8601/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103607278 CMS
ADC Therapeutics America, Inc. $3.5901/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1121191795 CMS
Genmab U.S., Inc. $27.3401/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1126825181 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $120.67 7
PY2020 $354.27 5
PY2021 $129.16 2
PY2022 $8,769.01 24
PY2023 $16,178.62 35
PY2024 $19,703.80 54
PY2025 $15,894.51 37

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $910,173.24 88
PY2024 Principal investigator $378,652.87 24
PY2023 Principal investigator $38,147.08 8
PY2022 Principal investigator $12,450.20 4
PY2021 Principal investigator $47,865.30 8
PY2020 Principal investigator $30,008.20 8
PY2019 Principal investigator $82,112.12 7

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

88 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 BeOne Medicines USA, Inc. $2,331.00 12/22/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190340733
Principal investigator 1 Genentech, Inc. $16,120.60 12/22/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211551554
Principal investigator 1 BeOne Medicines USA, Inc. $1,000.00 12/08/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190328649
Principal investigator 1 Genentech, Inc. $19,707.80 12/04/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211551557
Principal investigator 1 BeOne Medicines USA, Inc. $3,738.00 11/24/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190340738
Principal investigator 1 Genentech, Inc. $6,500.00 11/17/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211551551
Principal investigator 1 Genentech, Inc. $800.00 10/23/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211551534
Principal investigator 1 Genentech, Inc. $1,430.80 10/23/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211551539
Principal investigator 1 Genentech, Inc. $64,019.00 10/17/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211551547
Principal investigator 1 Genentech, Inc. $22,510.60 10/10/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211551543
Principal investigator 1 Genentech, Inc. $500.00 09/25/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211551526
Principal investigator 1 BeOne Medicines USA, Inc. $905.80 09/22/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190328639
Principal investigator 1 BeOne Medicines USA, Inc. $13,930.00 09/22/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190328645
Principal investigator 1 BeOne Medicines USA, Inc. $2,569.00 09/22/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190340724
Principal investigator 1 BeOne Medicines USA, Inc. $1,000.00 09/15/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190328643
Principal investigator 1 BeOne Medicines USA, Inc. $1,000.00 09/02/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190328635
Principal investigator 1 BeOne Medicines USA, Inc. $1,251.60 09/02/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190328637
Principal investigator 1 BeOne Medicines USA, Inc. $6,500.00 09/02/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190328641
Principal investigator 1 BeOne Medicines USA, Inc. $280.00 09/02/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190328647
Principal investigator 1 Genentech, Inc. $3,341.80 08/28/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211551518
Principal investigator 1 Genentech, Inc. $2,800.00 08/21/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211551530
Principal investigator 1 Genentech, Inc. $800.00 08/20/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211551513
Principal investigator 1 Genentech, Inc. $1,957.20 08/18/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211551508
Principal investigator 1 Genentech, Inc. $120.60 08/15/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
Polarix No dispute reported 06/30/2026 1211551436
Principal investigator 1 Genentech, Inc. $9,940.00 08/08/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211551522
Principal investigator 1 Genentech, Inc. $6,986.00 08/04/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211551496
Principal investigator 1 Genentech, Inc. $32,824.00 07/29/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211551504
Principal investigator 1 BeOne Medicines USA, Inc. $4,253.00 07/21/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190340728
Principal investigator 1 Genentech, Inc. $400.00 07/16/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211551500
Principal investigator 1 Genentech, Inc. $72,452.00 07/09/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211551492
Principal investigator 1 Genentech, Inc. $6,639.00 07/07/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211551488
Principal investigator 1 BeOne Medicines Ltd. $560.00 06/23/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190326872
Principal investigator 1 BeOne Medicines Ltd. $140.00 06/23/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190326880
Principal investigator 1 BeOne Medicines Ltd. $43,737.12 06/23/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia Dispute reported 06/30/2026 1190337309
Principal investigator 1 BeOne Medicines Ltd. $11,005.40 06/09/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190326876
Principal investigator 1 BeOne Medicines Ltd. $972.00 05/29/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190326868
Principal investigator 1 BeOne Medicines Ltd. $2,681.00 05/29/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190326870
Principal investigator 1 BeOne Medicines Ltd. $210.00 05/29/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190326874
Principal investigator 1 BeOne Medicines Ltd. $1,000.00 05/29/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190326878
Principal investigator 1 BeOne Medicines Ltd. $2,569.00 05/29/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190331123
Principal investigator 1 Genentech, Inc. $34,966.00 05/28/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211551440
Principal investigator 1 BeiGene, Ltd. $10,450.00 05/19/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190321142
Principal investigator 1 BeiGene, Ltd. $13,930.00 05/19/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190321146
Principal investigator 1 Genentech, Inc. $24,875.00 05/14/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211551464
Principal investigator 1 Genentech, Inc. $887.60 05/13/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211551468
Principal investigator 1 BeiGene, Ltd. $72,895.20 05/07/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia Dispute reported 06/30/2026 1190322258
Principal investigator 1 Genentech, Inc. $6,986.00 05/05/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211551460
Principal investigator 1 Genentech, Inc. $830.20 04/29/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211551479
Principal investigator 1 BeiGene, Ltd. $10,728.20 04/28/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190321138
Principal investigator 1 BeiGene, Ltd. $280.00 04/28/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190321140
Principal investigator 1 BeiGene, Ltd. $5,392.80 04/28/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190321144
Principal investigator 1 BeiGene, Ltd. $11,005.40 04/28/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190321148
Principal investigator 1 BeiGene, Ltd. $14,579.04 04/23/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia Dispute reported 06/30/2026 1190323894
Principal investigator 1 BeiGene, Ltd. $9,207.00 04/21/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190322482
Principal investigator 1 BeiGene, Ltd. $4,144.00 04/16/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190322480
Principal investigator 1 BeiGene, Ltd. $14,579.04 04/14/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia Dispute reported 06/30/2026 1190322238
Principal investigator 1 Genentech, Inc. $13,391.00 04/09/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211551475
Principal investigator 1 Genentech, Inc. $800.00 04/08/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211551456
Principal investigator 1 Genentech, Inc. $54.60 04/08/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211551471
Principal investigator 1 BeiGene, Ltd. $14,579.04 04/02/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia Dispute reported 06/30/2026 1190323872
Principal investigator 1 BeOne Medicines USA, Inc. $420.00 03/31/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190328651
Principal investigator 1 BeiGene, Ltd. $695.80 03/31/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190322790
Principal investigator 1 BeiGene, Ltd. $971.60 03/31/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190322792
Principal investigator 1 BeiGene, Ltd. $500.00 03/31/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190322802
Principal investigator 1 BeiGene, Ltd. $350.00 03/17/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190322788
Principal investigator 1 BeiGene, Ltd. $1,000.00 03/17/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190322794
Principal investigator 1 BeiGene, Ltd. $914.20 03/17/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190322804
Principal investigator 1 BeiGene, Ltd. $7,289.52 03/17/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190323840
Principal investigator 1 BeiGene, Ltd. $7,289.52 03/17/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia Dispute reported 06/30/2026 1190323842
Principal investigator 1 Genentech, Inc. $3,620.00 03/17/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211551452
Principal investigator 1 Genentech, Inc. $900.00 03/17/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211551483
Principal investigator 1 BeiGene, Ltd. $14,579.04 03/03/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia Dispute reported 06/30/2026 1190322224
Principal investigator 1 BeiGene, Ltd. $16,647.00 02/24/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190322476
Principal investigator 1 BeiGene, Ltd. $14,579.04 02/17/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190323774
Principal investigator 1 BeiGene, Ltd. $14,579.04 01/30/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia Dispute reported 06/30/2026 1190325432
Principal investigator 1 BeiGene, Ltd. $15,720.00 01/30/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia Dispute reported 06/30/2026 1190325434
Principal investigator 1 Genentech, Inc. $10,149.00 01/28/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211551444
Principal investigator 1 Genentech, Inc. $19,000.00 01/28/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211551449
Principal investigator 1 BeiGene, Ltd. $1,190.00 01/27/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190322796
Principal investigator 1 BeiGene, Ltd. $500.00 01/27/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190322800
Principal investigator 1 BeiGene, Ltd. $31,440.00 01/22/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia Dispute reported 06/30/2026 1190323766
Principal investigator 1 BeiGene, Ltd. $39,504.00 01/21/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190322478
Principal investigator 1 BeiGene, Ltd. $3,500.00 01/21/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190322798
Principal investigator 1 BeiGene, Ltd. $21,868.56 01/21/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia Dispute reported 06/30/2026 1190323758
Principal investigator 1 BeiGene, Ltd. $8,612.72 01/15/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia Dispute reported 06/30/2026 1190323802
Principal investigator 1 BeiGene, Ltd. $15,120.00 01/06/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia Dispute reported 06/30/2026 1190323736
Principal investigator 1 BeiGene, Ltd. $8,612.72 01/06/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia Dispute reported 06/30/2026 1190323738
Principal investigator 1 BeiGene, Ltd. $14,579.04 01/06/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia Dispute reported 06/30/2026 1190323740